Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.

Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

Blocking TYK2 might be a new way to treat hair loss from alopecia areata.

Topical IKKα inhibitors may help prevent CCS tumours.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

The FDA approved a new Pfizer drug for hair loss in teens.